ArticleCureus2026
Early-Onset Colorectal and Gastric Adenocarcinomas in a Patient With a Heterozygous BLM p.E1317K Variant of Uncertain Significance.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-onset gastrointestinal malignancies may raise concerns for hereditary cancer susceptibility, although interpretation of rare germline variants identified through multigene testing remains challenging. We describe the case of a male patient diagnosed with stage IIIB mismatch repair-proficient sigmoid adenocarcinoma at age 29 who subsequently developed a poorly differentiated gastric adenocarcinoma five years later. Germline testing identified a heterozygous BLM p.E1317K variant of uncertain significance (VUS) and no other pathogenic germline alterations. Both tumors demonstrated microsatellite-stable, mismatch repair-proficient disease with low tumor mutational burden, and the patient's family history was notable for gastric cancer in his father, collectively raising concern for an underlying cancer predisposition. Although Bloom syndrome is associated with biallelic pathogenic BLM variants, the oncologic significance of heterozygous BLM alterations remains incompletely defined. This report highlights the interpretive challenges surrounding rare germline variants in patients with multiple early-onset gastrointestinal malignancies and underscores the need for further investigation into the potential role of selected heterozygous BLM variants in cancer susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.